Eli Lilly (NYSE: LLY) has transformed from a steady pharmaceutical giant into one of Wall Street’s standout growth ...

SiteOne Therapeutics is developing a non-opioid therapy that targets sodium ion channels in the human body to treat pain and ...

Lilly in February announced plans to add four U.S. manufacturing sites at yet-to-be-determined sites as part of a roughly $27 billion investment.

But shares of Eli Lilly have gained about 800% since that same month, when CEO Dave Ricks took over the company. Mounting pressure also came from the powerful Novo Nordisk Foundation ...

But shares of Eli Lilly have gained about 800% since that same month, when CEO Dave Ricks took over the company. Feeling out of the loop? We'll catch you up on the news you need to know with the ...

WestEnd Advisors LLC grew its position in Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after purchasing ...

Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

Novo Nordisk CEO Lars Fruergaard Jorgensen is stepping down as competition in the weight-loss drug space pressured the company's stock ... rivals such as Eli Lilly to dominate the highly ...